{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:33Z","timestamp":1790383833577,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ACRAF Spa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Acute bacterial skin and skin structure infections (ABSSSI) and osteoarticular infections compound the burden of morbidity, mortality and prolonged hospitalizations among gram-positive infections. Dalbavancin, a second-generation, intravenous lipoglycopeptide, due to its prolonged half-life, can be a valuable alternative in their treatment when administered as inpatient treatment at the price of an extended hospital stay. Between October 2019 and September 2023, 31 children and adolescents were treated with dalbavancin because of bone and joint infections (n = 12 patients, 39%), ABSSSI (n = 13 patients, 42%), mainly for the limbs, facial cellulitis or complicated ABSSSI (n = 6 patients, 19%), at five Italian pediatric centers. Microbiological study provided gram-positive bacterial isolate in 16 cases, in 11 cases from a positive blood culture; 9 of them were MRSA. Twenty-five patients were initially treated with a different antibiotic therapy: beta-lactam-based in 18 patients (58%), glycopeptide-based in 15 patients (48%) and daptomycin in 6 (19%). The median time that elapsed between admission and start of dalbavancin was 18 days. A total of 61 doses of dalbavancin were administered to the 31 patients: 16 received a single dose while the remaining 15 patients received between two (n = 9) and nine doses. The frequency of administration was weekly in five cases or fortnightly in nine patients. Median length of stay in hospital was 16 days. Median time to discharge after the first dose of dalbavancin was 1 day. Treatment was very well-tolerated: of the 61 administered doses, only four doses, administered to four patients, were associated with an adverse event: drug extravasation during intravenous administration occurred in two patients, with no sequelae; however, in two patients the first administration was stopped soon after infusion start: in one (ID #11), due to headache and vomiting; in another (ID #12) due to a systemic reaction. In both patients, drug infusion was not repeated. None of the remaining 29 patients reported treatment failure (resistant or recurrent disease) or an adverse effect during a median follow-up time of two months. The use of dalbavancin was safe, feasible and also effective in shortening the hospital stay in children and adolescents.<\/jats:p>","DOI":"10.3390\/children11010078","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:48:06Z","timestamp":1704797286000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5716-3703","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"Caselli","sequence":"first","affiliation":[{"name":"Infectious Diseases, Children\u2019s Hospital Giovanni XXIII, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-7301","authenticated-orcid":false,"given":"Marcello","family":"Mariani","sequence":"additional","affiliation":[{"name":"Pediatrics and Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Colomba","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Maternal and Child Care, Internal Medicine and Medical Specialties \u201cG. D\u2019Alessandro\u201d, University of Palermo, 90133 Palermo, Italy"},{"name":"Division of Pediatric Infectious Diseases, \u201cG. Di Cristina\u201d Hospital, ARNAS Civico Di Cristina Benfratelli, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ferrecchi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, 16126 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-1679","authenticated-orcid":false,"given":"Claudio","family":"Cafagno","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Children\u2019s Hospital Giovanni XXIII, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Trotta","sequence":"additional","affiliation":[{"name":"Pediatrics, S. Spirito Hospital, A.S.L. Pescara, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Carloni","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Health, Salesi Children\u2019s Hospital, 60123 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dibello","sequence":"additional","affiliation":[{"name":"Pediatric Orthopedics and Traumatology, Children\u2019s Hospital Giovanni XXIII, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-8429","authenticated-orcid":false,"given":"Elio","family":"Castagnola","sequence":"additional","affiliation":[{"name":"Pediatrics and Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-6671","authenticated-orcid":false,"given":"Maurizio","family":"Aric\u00f2","sequence":"additional","affiliation":[{"name":"Pediatrics, S. Spirito Hospital, A.S.L. Pescara, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1469-0691.2010.03365.x","article-title":"Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control","volume":"16","author":"Gould","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","article-title":"National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections","volume":"168","author":"Hersh","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jpedsurg.2011.05.008","article-title":"Increasing national burden of hospitalizations for skin and soft tissue infections in children","volume":"46","author":"Lautz","year":"2011","journal-title":"J. Pediatr. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1542\/peds.2012-0746","article-title":"Trends in resource utilization for hospitalized children with skin and soft tissue infections","volume":"131","author":"Lopez","year":"2013","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijantimicag.2017.03.004","article-title":"Old antimicrobials and Gram-positive cocci through the example of infective endocarditis and bone and joint infections","volume":"49","author":"Seng","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/678056","article-title":"Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection","volume":"35","author":"Jenkins","year":"2014","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/INF.0000000000000304","article-title":"Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection","volume":"33","author":"Moore","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sette, C., Mariani, M., Grasselli, L., Mesini, A., Saffioti, C., Russo, C., Bandettini, R., Moscatelli, A., Ramenghi, L.A., and Castagnola, E. (2023). Real-Life Vancomycin Therapeutic Drug Monitoring in Coagulase-Negative Staphylococcal Bacteremia in Neonatal and Pediatric Intensive Care Unit: Are We Underestimating Augmented Renal Clearance?. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111566"},{"key":"ref_9","unstructured":"(2023, December 01). Available online: https:\/\/antibiotic.ecdc.europa.eu\/en."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dimopoulou, D., Mantadakis, E., Koutserimpas, C., and Samonis, G. (2023). A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12101492"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14787210.2023.2182769","article-title":"Acute bacterial skin and skin structure infections in pediatric patients: Potential role of dalbavancin","volume":"21","author":"Volpicelli","year":"2023","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0000000000003798","article-title":"The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients with Acute Bacterial Skin and Skin Structure Infections","volume":"42","author":"Giorgobiani","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/INF.0000000000003764","article-title":"Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients","volume":"42","author":"Carrothers","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_15","unstructured":"(2023, November 24). Xydalba|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xydalba#:~:text=Xydalba%20is%20an%20antibiotic%20used,skin%20abscesses%20and%20wound%20infections."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ejhpharm-2020-002315","article-title":"Effectiveness, safety and cost analysis of dalbavancin in clinical practice","volume":"29","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMp2031891","article-title":"Vancomycin Infusion Reaction\u2014Moving beyond \u201cRed Man Syndrome\u201d","volume":"384","author":"Ogunwole","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guest, J.F., Esteban, J., Manganelli, A.G., Novelli, A., Rizzardini, G., and Serra, M. (2017). Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187792"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14787210.2020.1746643","article-title":"The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs)","volume":"18","author":"Soriano","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/QCO.0000000000000430","article-title":"The role of dalbavancin in skin and soft tissue infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","article-title":"Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Rappo","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1120009X.2017.1311398","article-title":"Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: An update","volume":"29","author":"Esposito","year":"2017","journal-title":"J. Chemother."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/1\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:43:01Z","timestamp":1760103781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/1\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["children11010078"],"URL":"https:\/\/doi.org\/10.3390\/children11010078","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}